miR-340 Reverses Cisplatin Resistance of Hepatocellular Carcinoma Cell Lines by Targeting Nrf2-dependent Antioxidant Pathway

Shi, Liang,Chen, Zhan-Guo,Wu, Li-li,Zheng, Jian-Jian,Yang, Jian-Rong,Chen, Xiao-Fei,Chen, Zeng-Qiang,Liu, Cun-Li,Chi, Sheng-Ying,Zheng, Jia-Ying,Huang, Hai-Xia,Lin, Xiang-Yang,Zheng, Fang Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.23

Many chemotherapeutic agents have been successfully used to treat hepatocellular carcinoma (HCC); however, the development of chemoresistance in liver cancer cells usually results in a relapse and worsening of prognosis. It has been demonstrated that DNA methylation and histone modification play crucial roles in chemotherapy resistance. Currently, extensive research has shown that there is another potential mechanism of gene expression control, which is mediated through the function of short noncoding RNAs, especially for microRNAs (miRNAs), but little is known about their roles in cancer cell drug resistance. In present study, by taking advantage of miRNA effects on the resistance of human hepatocellular carcinoma cells line to cisplatin, it has been demonstrated that miR-340 were significantly downregulated whereas Nrf2 was upregulated in HepG2/CDDP (cisplatin) cells, compared with parental HepG2 cells. Bioinformatics analysis and luciferase assays of Nrf2-3'-untranslated region-based reporter constructor indicated that Nrf2 was the direct target gene of miR-340, miR-340 mimics suppressing Nrf2-dependent antioxidant pathway and enhancing the sensitivity of HepG2/CDDP cells to cisplatin. Interestingly, transfection with miR-340 mimics combined with miR-340 inhibitors reactivated the Nrf2 related pathway and restored the resistance of HepG2/CDDP cells to CDDP. Collectively, the results first suggested that lower expression of miR-340 is involved in the development of CDDP resistance in hepatocellular carcinoma cell line, at least partly due to regulating Nrf2-dependent antioxidant pathway.

JAK2-STAT5 signaling is insensitive to porcine growth hormone (pGH) in hepatocytes of neonatal pig

Yang Yu-Jiang,Zheng Xin,Lan Hai-Nan 한국통합생물학회 2020 Animal cells and systems Vol.24 No.2

Porcine growth hormone (pGH) is most important hormone which is involved in the growth and development of pig. However, a series of studies have indicated that neonatal pig is insensitive to pGH; the reason for this phenomenon is still not fully understood. In this work, we try to investigate this issue from the angle of intracellular signaling induced by pGH. In the present study, porcine hepatocytes from neonatal pig were used as a model, and confocal laser scanning microscopy (CLSM), Western blot, co-immunoprecipitation and colocalization assay were used to study pGH’s signaling properties in hepatocytes of neonatal pig and explore the possible mechanism(s) for why intracellular signaling is insensitive to pGH. The results indicated that Janus kinase 2 and signal transducers and activators of transcription 5/3/1 (JAK2-STATs) signaling are not activated. We further investigated the possible mechanism(s) by which JAK2-STATs’ signaling is not activated by pGH and growth hormone receptor (GHR) and found that the negative regulatory molecules of JAK2-STATs signaling may be associated with this phenomenon in the hepatocytes of neonatal pig. In addition, we also explored pGH’s biology in hepatocytes from neonatal pig, it can be found that pGH/GHR could translocate into the cell nucleus, which implies that pGH/GHR may exhibit physiological roles based on their nuclear localization. We found that pGH could not trigger intracellular signaling in the hepatocytes of neonatal pigs, but not young pigs, which provides an important explanation for why the growth of neonatal pig is GH independent.

Clinical and Histopathological Analysis of 66 Cases with Cardiac Myxoma

Zheng, Jian-Jie,Geng, Xi-Gang,Wang, Hai-Chen,Yan, Yang,Wang, Hong-Yan Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.3

Background and Purpose: Cardiac myxoma is a major primary heart tumor which often causes unexpected symptoms or sudden death. This present study was designed to investigate its clinical pathological features and biological behavior. Methods: A retrospective analysis of the clinical pathologic and immunohistochemical features of 66 cases with cardiac myxoma was conducted. Results: In 66 patients with cardiac myxoma, 61 cases had involvement of the left atrium, one case in both the right ventricular and left atria. The female: male ratio was 2.7:1. Patients had symptoms of blood flow obstruction and systemic alterations with performance of arterial embolization. Tumors were spherical, lobulated or irregular in shape, and soft and brittle. Immunohistochemical markers of vimentin and CD34 in tumor cells were positive. Conclusion: Cardiac myxoma always exists in the left atrium and is more common in women, with diverse clinical manifestations and pathomorphism. Although proliferative activity and the recurrence rate are low, in addition to thorough surgical resection, strengthened review is important for young patients.

Direct Palladium-Catalyzed C-4 Arylation of Tri-substituted Furans with Aryl Chlorides: An Efficient Access to Heteroaromatics

Yang, Hai,Zheng, Zhishuo,Zeng, Jian,Liu, Huajie,Yi, Bing Korean Chemical Society 2012 Bulletin of the Korean Chemical Society Vol.33 No.8

A series of functionalized furans were synthesized by way of a palladium-catalyzed coupling reaction of 2,3,5-trisubstituted furans with aryl chlorides through C-H bond cleavages at C-4 position. The feature of the reaction was facilitative preparation of furan derivatives with good functional group tolerance. All reactions gave the desired products in moderate to good yields in the presences of $BuAd_2P$ and t-BuOK in DMF at $120^{\circ}C$ after 15 h.

Methylated Alteration of SHP1 Complements Mutation of JAK2 Tyrosine Kinase in Patients with Myeloproliferative Neoplasm

Yang, Jun-Jun,Chen, Hui,Zheng, Xiao-Qun,Li, Hai-Ying,Wu, Jian-Bo,Tang, Li-Yuan,Gao, Shen-Meng Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.6

SHP1 negatively regulates the Janus kinase 2/signal transducer and activator of transcription (JAK2/STAT) signaling pathway, which is constitutively activated in myeloproliferative neoplasms (MPNs) and leukemia. Promoter hypermethylation resulting in epigenetic inactivation of SHP1 has been reported in myelomas, leukemias and other cancers. However, whether SHP1 hypermethylation occurs in MPNs, especially in Chinese patients, has remained unclear. Here, we report that aberrant hypermethylation of SHP1 was observed in several leukemic cell lines and bone marrow mononuclear cells from MPN patients. About 51 of 118 (43.2%) MPN patients including 23 of 50 (46%) polycythaemia vera patients, 20 of 50 (40%) essential thrombocythaemia and 8 of 18 (44.4%) idiopathic myelofibrosis showed hypermethylation by methylation-specific polymerase chain reaction. However, SHP1 methylation was not measured in 20 healthy volunteers. Hypermethylation of SHP1 was found in MPN patients with both positive (34/81, 42%) and negative (17/37, 45.9%) JAK2V617F mutation. The levels of SHP1 mRNA were significantly lower in hypermethylated samples than unmethylated samples, suggesting SHP1 may be epigenetically inactivated in MPN patients. Furthermore, treatment with 5-aza-2'-deoxycytidine (AZA) in K562 cells showing hypermethylation of SHP1 led to progressive demethylation of SHP1, with consequently increased reexpression of SHP1. Meanwhile, phosphorylated JAK2 and STAT3 were progressively reduced. Finally, AZA increased the expression of SHP1 in primary MPN cells with hypermethylation of SHP1. Therefore, our data suggest that epigenetic inactivation of SHP1 contributes to the constitutive activation of JAK2/STAT signaling. Restoration of SHP1 expression by AZA may contribute to clinical treatment for MPN patients.

Direct Palladium-Catalyzed C-4 Arylation of Tri-substituted Furans with Aryl Chlorides: An Efficient Access to Heteroaromatics

Hai Yang,Zhishuo Zheng,Jian Zeng,Huajie Liu,Bing Yi 대한화학회 2012 Bulletin of the Korean Chemical Society Vol.33 No.8

A series of functionalized furans were synthesized by way of a palladium -catalyzed coupling reaction of 2,3,5- trisubstituted furans with aryl chlorides through C-H bond cleavages at C-4 position. The feature of the reaction was facilitative preparation of furan derivatives with good functional group tolerance. All reactions gave the desired products in moderate to good yields in the presences of BuAd2P and t-BuOK in DMF at 120 oC after 15 h.

Fluorine-doped porous carbon-decorated Fe₃O₄-FeF₂ composite versus LiNi_0.5Mn_1.5O₄ towards a full battery with robust capability

Ming, Hai,Ming, Jun,Kwak, Won-Jin,Yang, Wenjing,Zhou, Qun,Zheng, Junwei,Sun, Yang-Kook Elsevier 2015 ELECTROCHIMICA ACTA Vol.169 No.-

<P><B>Abstract</B></P> <P>A new fluorine-doped porous carbon-decorated Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB> composite, referred to as Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB>@CF<SUB>x</SUB>, was prepared for the first time. The formation mechanism is discussed, and a new concept of introducing double layers of FeF<SUB>2</SUB> and CF<SUB>x</SUB> into the oxide-based anode is presented for lithium ion batteries. Varying the amount of fluorine precursor, derivatives of Fe<SUB>3</SUB>O<SUB>4</SUB>@CF<SUB>x</SUB> and FeF<SUB>2</SUB>@CF<SUB>x</SUB> were further obtained, allowing an original analysis of their electrochemical behaviors. As-prepared Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB>@CF<SUB>x</SUB> can deliver a high capacity of 718mAhg<SUP>−1</SUP> at 50mAg<SUP>−1</SUP>. Under a hash rate of 1600mAg<SUP>−1</SUP>, the capacity of Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB>@CF<SUB>x</SUB> (around 338mAhg<SUP>−1</SUP>) is higher than that (200mAhg<SUP>−1</SUP>) of FeF<SUB>2</SUB>@CF<SUB>x</SUB>. Further, its capacity retention of 97% over 100 cycles is much better than the 59.4% observed for Fe<SUB>3</SUB>O<SUB>4</SUB>@CF<SUB>x</SUB>. The positive effect of the CF<SUB>x</SUB> layer on the electronic conductivity and ionic diffusion ability was confirmed. The role of FeF<SUB>2</SUB> in the stabilization of the structure of CF<SUB>x</SUB> and Fe<SUB>3</SUB>O<SUB>4</SUB> is also discussed. Further, a new battery composed of Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB>@CF<SUB>x</SUB>/LiNi<SUB>0.5</SUB>Mn<SUB>1.5</SUB>O<SUB>4</SUB> with a robust rate capability was assembled and delivered a reversible capacity of 565mAhg<SUP>−1</SUP> (<I>vs.</I> anode) at 100mAg<SUP>−1</SUP> with a high potential of 3.3V and a capacity retention of 81.5% over 50 cycles.</P> <P><B>Highlights</B></P> <P> <UL> <LI> A new anode of fluorine-doped porous Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB>@CF<SUB>x</SUB> composite is readily prepared. </LI> <LI> The CF<SUB>x</SUB> layer enhances the conductivity of Fe<SUB>3</SUB>O<SUB>4</SUB> and ensures a fast Li<SUP>+</SUP> diffusion. </LI> <LI> The FeF<SUB>2</SUB> can stabilize the structure of Fe<SUB>3</SUB>O<SUB>4</SUB> during the (dis) charge process. </LI> <LI> The Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB>@CF<SUB>x</SUB> can deliver a high capacity with a robust rate capability. </LI> <LI> A full cell of Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB>@CF<SUB>x</SUB>/LiNi<SUB>0.5</SUB>Mn<SUB>1.5</SUB>O<SUB>4</SUB> with high performance is assembled. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>A new anode of fluorine doped porous Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB>@CF<SUB>x</SUB> composite with double layers of FeF<SUB>2</SUB> and CF<SUB>x</SUB> was presented for the first time, and a high rate capability was obtained in lithium ion battery. Besides, a new full battery of Fe<SUB>3</SUB>O<SUB>4</SUB>-FeF<SUB>2</SUB>@CF<SUB>x</SUB>/LiNi<SUB>0.5</SUB>Mn<SUB>1.5</SUB>O<SUB>4</SUB> with a high capacity of 565mAhg<SUP>−1</SUP> (<I>vs</I>. anode) at the current density of 100mAg<SUP>−1</SUP> was successfully introduced. It demonstrated a robust rate capability, high operating potential of 3.3V and fine cycle ability over 50 cycles with capacity retention of 81.5%.</P> <P>[DISPLAY OMISSION]</P>

Clinical Study of Thalidomide Combined with Dexamethasone for the Treatment of Elderly Patients with Newly Diagnosed Multiple Myeloma

Chen, Hai-Fei,Li, Zheng-Yang,Tang, Jie-Qing,Shen, Hong-Shi,Cui, Qing-Ya,Ren, Yong-Ya,Qin, Long-Mei,Jin, Ling-Juan,Zhu, Jing-Jing,Wang, Jing,Ding, Jie,Wang, Ke-Yuan,Yu, Zi-Qiang,Wang, Zhao-Yue,Wu, Tian Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.9

Objective: To investigate the relationship between the efficacy and safety of different doses of thalidomide (Thal) plus dexamethasone (Dex) as the initial therapy in elderly patients with newly diagnosed multiple myeloma (MM). Methods: Clinical data of 28 elderly patients with newly diagnosed MM who underwent the TD regimen as the initial therapy were analyzed retrospectively. The patients were divided into two groups according to the maximal sustained dose of Thal: lower dose (group A) and higher dose (group B). The overall response rate (ORR), progression free survival (PFS), overall survival (OS), and adverse events (AES) were compared between the two groups. Results: A total of 28 patients were followed up with a median of 18 months. The ORR was 60.1%. The median response time and PFS were 2.0 and 17.0 months, respectively. The mean sustained dose of Thal in group B was significantly higher than group A (292.9 mg v 180.4 mg, P=0.01). There was no significantly difference in ORR (57.1% v 64.3%, P=1.00) and PFS (9.63months v 17.66 months, P=0.73) between groups A and B. During the follow up, only five patients died (<40%) and, therefore, median OS values were not available. It is estimated, however, that the mean survival time in the two groups was 35.6 and 33.4 months (P>0.05), respectively. All of the patients tolerated the treatment well. The incidence of AES in patients with a grading above 3 in group B was significantly higher than in group A (P=0.033). Conclusions: The TD regimen results in a high response rate and manageable AES as the initial therapy in elderly patients with MM. TD should be considered as the front line regimen for the treatment of elderly patients with MM in areas with financial constraints. The clinical response can be achieved at a low dose Thal with minimal toxicity.

Correlation of Adventitial Vasa Vasorum with Intracranial Atherosclerosis: A Postmortem Study

Lu Zheng,Wen Jie Yang,Chun Bo Niu,Hai Lu Zhao,Ka Sing Wong,Thomas Wai Hong Leung,Xiang Yan Chen 대한뇌졸중학회 2018 Journal of stroke Vol.20 No.3

Background and Purpose Vasa vasorum (VV) have been believed to be rare or non-existent in small-caliber intracranial arteries. In a series of human cerebral artery specimens, we identified and examined the distribution of VV in association with co-existing intracranial atherosclerosis. Methods We obtained cerebral artery specimens from 32 consecutive autopsies of subjects aged 45 years or above. We scrutinized middle cerebral artery (MCA), vertebral artery (VA), and basilar artery (BA) for the presence of adventitial VV. We described the distribution of VV, and the characteristics of co-existing atherosclerotic lesions. Results Among 157 intracranial arteries, adventitial VV were present in 74 of the 157 specimens (47%), involving MCA (n=13, 18%), BA (n=14, 19%), and VA (n=47, 64%). Although qualitatively these 74 adventitial VV distributed similarly in arteries with or without atherosclerotic lesions (disease-free arteries n=4/8; arteries of pre-atherosclerosis n=17/42; and arteries of progressive atherosclerosis n=53/107), the presence of adventitial VV in intracranial VA was associated with a heavier plaque load (1.72±1.66 mm2 vs. 0.40±0.32 mm2, P<0.001), severer luminal stenosis (25%±21% vs. 12%±9%, P=0.002), higher rate of concentric lesions (79% vs. 36%, P=0.002), and denser intraplaque calcification (44% vs. 0%, P=0.003). Histologically, intracranial VA with VV had a larger diameter (3.40±0.79 mm vs. 2.34±0.58 mm, P<0.001), thicker arterial wall (0.31±0.13 mm vs. 0.23±0.06 mm, P=0.002), and a larger intima-media (0.19±0.09 mm vs. 0.13± 0.04 mm, P=0.003) than VA without VV. Conclusions Our study demonstrated the distribution of adventitial VV within brain vasculature and association between vertebral VV and progressive atherosclerotic lesions with a heavier plaque load and denser intraplaque calcification.

Surfactant-Assisted Synthesis of Fe₂O₃ Nanoparticles and F-Doped Carbon Modification toward an Improved Fe₃O₄@CF_<i>x</i>/LiNi_0.5Mn_1.5O₄ Battery

Ming, Hai,Ming, Jun,Oh, Seung-Min,Tian, Shu,Zhou, Qun,Huang, Hui,Sun, Yang-Kook,Zheng, Junwei American Chemical Society 2014 ACS APPLIED MATERIALS & INTERFACES Vol.6 No.17

<P>A simple surfactant-assisted reflux method was used in this study for the synthesis of cocklebur-shaped Fe<SUB>2</SUB>O<SUB>3</SUB> nanoparticles (NPs). With this strategy, a series of nanostructured Fe<SUB>2</SUB>O<SUB>3</SUB> NPs with a size distribution ranging from 20 to 120 nm and a tunable surface area were readily controlled by varying reflux temperature and the type of surfactant. Surfactants such as cetyltrimethylammonium bromide (CTAB), polyvinylpyrrolidone (PVP), poly(ethylene glycol)-<I>block</I>-poly(propylene glycol)-<I>block</I>-poly(ethylene glycol) (F127) and sodium dodecyl benzenesulfonate (SDBS) were used to achieve large-scale synthesis of uniform Fe<SUB>2</SUB>O<SUB>3</SUB> NPs with a relatively low cost. A new composite of Fe<SUB>3</SUB>O<SUB>4</SUB>@CF<SUB><I>x</I></SUB> was prepared by coating the primary Fe<SUB>2</SUB>O<SUB>3</SUB> NPs with a layer of F-doped carbon (CF<SUB><I>x</I></SUB>) with a one-step carbonization process. The Fe<SUB>3</SUB>O<SUB>4</SUB>@CF<SUB><I>x</I></SUB> composite was utilized as the anode in a lithium ion battery and exhibited a high reversible capacity of 900 mAh g<SUP>–1</SUP> at a current density of 100 mA g<SUP>–1</SUP> over 100 cycles with 95% capacity retention. In addition, a new Fe<SUB>3</SUB>O<SUB>4</SUB>@CF<SUB><I>x</I></SUB>/LiNi<SUB>0.5</SUB>Mn<SUB>1.5</SUB>O<SUB>4</SUB> battery with a high energy density of 371 Wh kg<SUP>–1</SUP> (vs cathode) was successfully assembled, and more than 300 cycles were easily completed with 66.8% capacity retention at 100 mA g<SUP>–1</SUP>. Even cycled at the high temperature of 45 °C, this full cell also exhibited a relatively high capacity of 91.6 mAh g<SUP>–1</SUP> (vs cathode) at 100 mA g<SUP>–1</SUP> and retained 54.6% of its reversible capacity over 50 cycles. Introducing CF<SUB><I>x</I></SUB> chemicals to modify metal oxide anodes and/or any other cathode is of great interest for advanced energy storage and conversion devices.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/aamick/2014/aamick.2014.6.issue-17/am504144d/production/images/medium/am-2014-04144d_0009.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/am504144d'>ACS Electronic Supporting Info</A></P>